c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun (original) (raw)

• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J clin invest 2011; 121: 2750–2767.
  Article CAS PubMed PubMed Central Google Scholar
• D'Amato NC, Ostrander JH, Bowie ML, Sistrunk C, Borowsky A, Cardiff RD et al. Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PloS one 2012; 7: e45684.
  Article CAS PubMed PubMed Central Google Scholar
• Kong D, Li Y, Wang Z, Sarkar FH . Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers 2011; 3: 716–729.
  Article PubMed PubMed Central Google Scholar
• Li F, Tiede B, Massague J, Kang Y . Beyond tumorigenesis: cancer stem cells in metastasis. Cell res 2007; 17: 3–14.
  Article CAS PubMed Google Scholar
• Economopoulou P, Kaklamani VG, Siziopikou K . The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. oncologist 2012; 17: 1394–1401.
  Article CAS PubMed PubMed Central Google Scholar
• Trosko JE . Review paper: cancer stem cells and cancer nonstem cells: from adult stem cells or from reprogramming of differentiated somatic cells. Vet pathol 2009; 46: 176–193.
  Article CAS PubMed Google Scholar
• McDermott SP, Wicha MS . Targeting breast cancer stem cells. Mol oncol 2010; 4: 404–419.
  Article CAS PubMed PubMed Central Google Scholar
• Park CY, Tseng D, Weissman IL . Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol ther 2009; 17: 219–230.
  Article CAS PubMed Google Scholar
• Chen F . JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer res 2012; 72: 379–386.
  Article CAS PubMed PubMed Central Google Scholar
• Cubero FJ, Zhao G, Trautwein C . JNK: a double-edged sword in tumorigenesis. Hepatology 2011; 54: 1470–1472.
  Article PubMed Google Scholar
• Bogoyevitch MA, Kobe B . Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol mol biol rev 2006; 70: 1061–1095.
  Article CAS PubMed PubMed Central Google Scholar
• Li JY, Wang H, May S, Song X, Fueyo J, Fuller GN et al. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J neuro-oncol 2008; 88: 11–17.
  Article CAS Google Scholar
• Chang Q, Chen J, Beezhold KJ, Castranova V, Shi X, Chen F . JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol cancer 2009; 8: 64.
  Article PubMed PubMed Central Google Scholar
• Wang X, Chao L, Li X, Ma G, Chen L, Zang Y et al. Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and 'triple-negative' breast cancers. Hum pathol 2010; 41: 401–406.
  Article CAS PubMed Google Scholar
• Yeh YT, Hou MF, Chung YF, Chen YJ, Yang SF, Chen DC et al. Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival. Int j cancer 2006; 118: 2678–2684.
  Article CAS PubMed Google Scholar
• Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T et al. Discovery of potent and selective covalent inhibitors of JNK. Chem biol 2012; 19: 140–154.
  Article CAS PubMed PubMed Central Google Scholar
• Kappelmann M, Bosserhoff A, Kuphal S . AP-1/c-Jun transcription factors: regulation and function in malignant melanoma. Eur j cell biol 2014; 93: 76–81.
  Article CAS PubMed Google Scholar
• Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI . Biological and clinical associations of c-jun activation in human breast cancer. Int j cancer 2000; 89: 177–186.
  Article CAS PubMed Google Scholar
• Xia Y, Yang W, Bu W, Ji H, Zhao X, Zheng Y et al. Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells. J biol chem 2013; 288: 19321–19329.
  Article CAS PubMed PubMed Central Google Scholar
• Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J et al. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. oncologist 2012; 17: 766–774.
  Article CAS PubMed PubMed Central Google Scholar
• Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671–679.
  Article CAS PubMed Google Scholar
• Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer res 2008; 68: 5405–5413.
  Article CAS PubMed Google Scholar
• Yoon CH, Kim MJ, Kim RK, Lim EJ, Choi KS, An S et al. c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene 2012; 31: 4655–4666.
  Article CAS PubMed Google Scholar
• Chaterjee M, van Golen KL . Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy. Bone marrow res 2011; 2011: 362938.
  Article PubMed PubMed Central Google Scholar
• Wang YJ, Bailey JM, Rovira M, Leach SD . Sphere-forming assays for assessment of benign and malignant pancreatic stem cells. Meth mol biol 2013; 980: 281–290.
  Article CAS Google Scholar
• Wojtaszek PA, Heasley LE, Siriwardana G, Berl T . Dominant-negative c-Jun NH2-terminal kinase 2 sensitizes renal inner medullary collecting duct cells to hypertonicity-induced lethality independent of organic osmolyte transport. J biol chem 1998; 273: 800–804.
  Article CAS PubMed Google Scholar
• Liu J, Lin A . Role of JNK activation in apoptosis: a double-edged sword. Cell res 2005; 15: 36–42.
  Article PubMed Google Scholar
• Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S . c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005; 106: 1382–1391.
  Article CAS PubMed PubMed Central Google Scholar
• Fujishita T, Aoki M, Taketo MM . JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Delta716) mice. Gastroenterology 2011; 140: 1556–1563 e1556.
  Article CAS PubMed Google Scholar
• Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J . JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer res 2014; 74: 2444–2454.
  Article CAS PubMed PubMed Central Google Scholar
• Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X . Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol cancer res 2010; 8: 266–277.
  Article PubMed PubMed Central Google Scholar
• Gozdecka M, Lyons S, Kondo S, Taylor J, Li Y, Walczynski J et al. JNK suppresses tumor formation via a gene-expression program mediated by ATF2. Cell rep 2014; 9: 1361–1374.
  Article CAS PubMed Google Scholar
• Liu H, Deng X, Shyu YJ, Li JJ, Taparowsky EJ, Hu CD . Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization. EMBO j 2006; 25: 1058–1069.
  Article CAS PubMed PubMed Central Google Scholar
• Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF . Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech dev 1999; 89: 115–124.
  Article CAS PubMed Google Scholar
• Liu J, Minemoto Y, Lin A . c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis. Mol cell biol 2004; 24: 10844–10856.
  Article CAS PubMed PubMed Central Google Scholar
• She QB, Chen N, Bode AM, Flavell RA, Dong Z . Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer res 2002; 62: 1343–1348.
  CAS PubMed Google Scholar
• Capaccione KM, Pine SR . The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 2013; 34: 1420–1430.
  Article CAS PubMed PubMed Central Google Scholar
• Leong KG, Karsan A . Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107: 2223–2233.
  Article CAS PubMed Google Scholar
• Wang J, Sullenger BA, Rich JN . Notch signaling in cancer stem cells. Adv exp med biol 2012; 727: 174–185.
  Article CAS PubMed Google Scholar
• Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS . Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast cancer res 2004; 6: R605–R615.
  Article CAS PubMed PubMed Central Google Scholar
• Malhotra GK, Zhao X, Band H, Band V . Shared signaling pathways in normal and breast cancer stem cells. J carcinogen 2011; 10: 38.
  Article Google Scholar
• Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer res 2010; 70: 709–718.
  Article CAS PubMed PubMed Central Google Scholar
• Cantrell MA, Ebelt ND, Pfefferle AD, Perou CM, Van Den Berg CL . c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression. Oncotarget 2015; 6: 11863–11881.
  Article PubMed PubMed Central Google Scholar
• Tsuiki H, Tnani M, Okamoto I, Kenyon LC, Emlet DR, Holgado-Madruga M et al. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer res 2003; 63: 250–255.
  CAS PubMed Google Scholar
• Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175–3182.
  Article CAS PubMed Google Scholar
• Cheng L, Ramesh AV, Flesken-Nikitin A, Choi J, Nikitin AY . Mouse models for cancer stem cell research. Toxicol pathol 2010; 38: 62–71.
  Article PubMed Google Scholar